Cancer of the Exocrine Pancreas: Surgery and Multimodal Treatment

  • Giuliano Barugola
  • Massimo Falconi
  • Fabio Zarantonello
  • Giuseppe Malleo
  • Claudio Bassi
  • Paolo Pederzoli
Part of the Updates in Surgery book series (UPDATESSURG)


The optimal management of pancreatic ductal carcinoma remains poorly defined. Radical resection is possible in about 20–30% of patients, with an overall 5-year survival rate of only 20% [1]. In recent years, perioperative morbidity and mortality have significantly decreased, and different clinical trials have suggested an important role for adjuvant therapy [2].


Pancreatic Cancer Multimodal Treatment Advanced Pancreatic Cancer Exocrine Pancreas Resected Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Picozzi VJ, Pisters PW, Vickers SM, Strasberg SM (2008) Strength of the evidence: adjuvant therapy for resected pancreatic cancer. J Gastrointest Surg 12(4):657–661PubMedCrossRefGoogle Scholar
  2. 2.
    Saif MW (2007) Controversies in the adjuvant treatment of pancreatic adenocarcinoma. JOP 8(5):545–52PubMedGoogle Scholar
  3. 3.
    Bramhall SR, Allum WH, Jones AG et al (1995) Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg 82(1):111–115PubMedCrossRefGoogle Scholar
  4. 4.
    Kayahara M, Nagakawa T, Ueno K et al (1993) An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determinant by autopsy and diagnostic imaging. Cancer 72:2118–2123PubMedCrossRefGoogle Scholar
  5. 5.
    Bassi C, Salvia R, Butturini G et al (2005) Value of regional lymphadenectomy in pancreatic cancer. HPB 7(2):87–92PubMedGoogle Scholar
  6. 6.
    Kennedy EP, Yeo CJ (2007) Pancreaticoduodenectomy with extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma. Surg Oncol Clin N Am 16(1):157–176PubMedCrossRefGoogle Scholar
  7. 7.
    Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403–2413PubMedGoogle Scholar
  8. 8.
    Oettle H, Neuhaus P (2007) Adjuvant therapy in pancreatic cancer: a critical appraisal. Drugs 67(16):2293–2310PubMedCrossRefGoogle Scholar
  9. 9.
    Klinkenbijl JH, Jeekel J, Sahmoud T et al (1999) Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230(6):776–782PubMedCrossRefGoogle Scholar
  10. 10.
    Ruano-Ravina A, Almazán Ortega R, Guedea F (2008) Intraoperative radiotherapy in pancreatic cancer: a systematic review. Radiother Oncol [Epub ahead of print]Google Scholar
  11. 11.
    Ishikawa T (2007) Is it relevant that intra-arterial chemotherapy may be effective for advanced pancreatic cancer? World J Gastroenterol 13(32):4306–4309PubMedGoogle Scholar
  12. 12.
    Hoffman JP, Lipsitz S, Pisansky T et al (1998) Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol 16(1):317–323PubMedGoogle Scholar
  13. 13.
    Pedrazzoli S, Pasquali C, Sperti C (2002) Extent of lymphadenectomy in the resection of pancreatic cancer. Analysis of the existing evidence. Rocz Akad Med Bialymst 50:85–90Google Scholar
  14. 14.
    Greene FL, Page DL, Fleming ID et al (eds) (2002) AJCC Cancer Staging Manual, 6th edn. Springer, New York, pp 157–164Google Scholar
  15. 16.
    Neoptolemos JP, Stocken DD, Friess H et al (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350(12): 1200–1210PubMedCrossRefGoogle Scholar
  16. 17.
    Barugola G, Falconi M, Bettini R et al (2007) The determinant factors of recurrence following resection for ductal pancreatic cancer. JOP 8(1 Suppl):132–140PubMedGoogle Scholar
  17. 18.
    Westerdahl J, Andren-Sandberg A, Ihse I (1993) Recurrence of exocrine pancreatic cancer — local or hepatic? Hepatogastroenterology 40(4):384–387PubMedGoogle Scholar
  18. 19.
    Lim JE, Chien MW, Earle CC (2003) Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 237(1):74–85PubMedCrossRefGoogle Scholar
  19. 20.
    Klinkenbijl JH, van der Schelling GP, Hop WC et al (1992) The advantages of pylorus-preserving pancreatoduodenectomy in malignant disease of the pancreas and periampullary region. Ann Surg 216(2): 142–145PubMedCrossRefGoogle Scholar
  20. 21.
    Kleeff J, Michalski C, Friess H, Buchler MW (2006) Pancreatic cancer: from bench to 5-year survival. Pancreas 33(2): 111–118PubMedCrossRefGoogle Scholar
  21. 22.
    Köninger J, Wente MN, Müller-Stich BP et al (2008) R2 resection in pancreatic cancer-does it make sense? Langenbecks Arch Surg [Epub ahead of print]Google Scholar
  22. 23.
    Butturini G, Stocken DD, Moritz N et al (2008) Influence of resection margins and treatment on survival in patients with pancreatic cancer. Meta-analysis of randomized controlled trials. Arch Surg 143(1):75–83PubMedCrossRefGoogle Scholar
  23. 24.
    Oettle H, Neuhaus P (2007)Adjuvant therapy in pancreatic cancer: a critical appraisal. Drugs 67(16): 2293–2310PubMedCrossRefGoogle Scholar
  24. 25.
    Evans DB, for The Multidisciplinary Pancreatic Cancer Study Group (2006) Resectable pancreatic cancer: the role for neoadjuvant/preoperative therapy. HPB (Oxford) 8(5): 365–368Google Scholar
  25. 26.
    Greer SE, Pipas JM, Sutton JE et al (2008) Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma. J Am Coll Surg 206(3): 451–457PubMedGoogle Scholar
  26. 27.
    Stieler J (2008) Immunotherapeutic approaches in pancreatic cancer. Recent results. Cancer Res 177:165–177Google Scholar
  27. 28.
    Demirer T, Barkholt L, Blaise D et al (2008) Solid Tumors Working Party. Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. Nat Clin Pract Oncol [Epub ahead of print]Google Scholar
  28. 29.
    Hecht JR, Bedford R, Abbruzzese JL et al (2003) A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 9(2): 555–561PubMedGoogle Scholar
  29. 30.
    Picozzi VJ, Kozarek RA, Traverso LW (2003) Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 185(5): 476–480PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2009

Authors and Affiliations

  • Giuliano Barugola
    • 1
  • Massimo Falconi
    • 1
  • Fabio Zarantonello
    • 1
  • Giuseppe Malleo
    • 1
  • Claudio Bassi
    • 1
  • Paolo Pederzoli
    • 1
  1. 1.Department of SurgeryPoliclinico “GB Rossi”VeronaItaly

Personalised recommendations